Matching slides 303,780
Current window 203,551-203,580
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

203,551-203,580 of 303,780

filter-aware
14
Blue Water Vaccines | Results Presentation Deck | 15 slidesBlue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
Blue Water Vaccines | Results Presentation Deck | 15 slidesBlue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · Action1 hit
01
Slide 1
BNY Mellon | Results Presentation Deck | 18 slidesBNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Financial Highlights1 hit
02
Includes non-GAAP reconciliation footnotes.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Financial HighlightsLoop · Cost Of Inaction1 hit
03
Includes non-GAAP adjustments for notable items.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Financial HighlightsLoop · Cost Of Inaction1 hit
04
Includes footnotes referenced as (a) and (b).BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment PerformanceLoop · Cost Of Inaction1 hit
05
BNY Mellon | Results Presentation Deck | 18 slidesBNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment PerformanceLoop · Cost Of Inaction1 hit
06
Includes a non-GAAP reconciliation note regarding notable items.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment Performance1 hit
07
Includes footnotes referencing Appendix page 12.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment Performance1 hit
08
Includes footnotes reference to page 12.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment Performance1 hit
09
Includes footnotes regarding non-GAAP measures and specific reporting units.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment Performance1 hit
10
BNY Mellon | Results Presentation Deck | 18 slidesBNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Business Segment Performance1 hit
11
BNY Mellon | Results Presentation Deck | 18 slidesBNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Appendix1 hit
12
BNY Mellon | Results Presentation Deck | 18 slidesBNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Appendix1 hit
13
The slide presents three distinct sub-tables: total fee revenue impact, impact by line of business for investment services, and total impact to revenue by line of business.BNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Appendix1 hit
18
BNY Mellon | Results Presentation Deck | 18 slidesBNY Mellon | Results Presentation Deck | 18 slides · BNY Mellon
Conference presentation Investor relations Beat · Appendix1 hit
01
Slide 1
BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slidesBrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · Problem1 hit
02
The chart is a dot plot comparing baseline ALSFRS-R scores across various clinical trials, highlighting NurOwn's lower baseline.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slidesBrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
05
The slide uses a timeline-based process diagram to explain the clinical trial structure.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
07
The slide outlines the primary endpoint (Clinical Response) and a secondary/supporting metric (piecewise slope) for ALS clinical trials.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
08
The slide details the specific biomarkers used in the study and the exclusion criteria based on missing data.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
The slide uses a consistent color scheme (blue for NurOwn, red for Placebo) and indicates statistical significance with asterisks.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
11
The slide uses line charts with error bars to compare treatment effects across two subgroups (<=25 and >25 baseline ALSFRS-R).BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · Solution1 hit
12
The slide uses four line charts to demonstrate treatment effects on biomarkers, showing statistical significance markers.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · Solution1 hit
13
The slide uses color-coding to link specific biomarkers to biological pathways.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · Solution1 hit
01
Slide 1
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
02
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
03
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
04
Note the typo in 'OPPENING' on the slide.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit